Published in Fam Cancer on January 01, 2006
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res (2008) 3.05
Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol (2011) 2.33
Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Res (2008) 2.06
Hereditary breast cancer: new genetic developments, new therapeutic avenues. Hum Genet (2008) 1.96
Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival. Mol Pharmacol (2009) 1.33
Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res Treat (2010) 1.11
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells. BMC Pharmacol (2011) 1.09
Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. Breast Cancer Res (2010) 1.09
Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation. Br J Cancer (2010) 1.06
BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br J Cancer (2013) 1.03
Small molecule inhibitor of the RPA70 N-terminal protein interaction domain discovered using in silico and in vitro methods. Bioorg Med Chem (2011) 1.01
Hereditary breast cancer: the era of new susceptibility genes. Biomed Res Int (2013) 1.01
BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. J Clin Invest (2016) 0.94
Hereditary breast cancer: pathobiology, clinical translation, and potential for targeted cancer therapeutics. Fam Cancer (2007) 0.90
DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1. BMC Cancer (2012) 0.88
Predictive modeling using a somatic mutational profile in ovarian high grade serous carcinoma. PLoS One (2013) 0.87
Outcome of metastatic breast cancer in selected women with or without deleterious BRCA mutations. Clin Exp Metastasis (2013) 0.86
BRCA1/2 genetic background-based therapeutic tailoring of human ovarian cancer: hope or reality? J Ovarian Res (2009) 0.84
New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches. Biomed Res Int (2013) 0.84
Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer. J Drug Deliv (2013) 0.83
Growth factor receptors and apoptosis regulators: signaling pathways, prognosis, chemosensitivity and treatment outcomes of breast cancer. Breast Cancer (Auckl) (2009) 0.82
Response to neo-adjuvant chemotherapy in BRCA1 and BRCA2 related stage III breast cancer. Fam Cancer (2008) 0.80
Eleven years disease-free: role of chemotherapy in metastatic BRCA2-related breast cancer. Nat Rev Clin Oncol (2009) 0.80
Recent advances in managing triple-negative breast cancers. F1000 Med Rep (2009) 0.79
Expression Levels of DNA Damage Repair Proteins Are Associated With Overall Survival in Platinum-Treated Advanced Urothelial Carcinoma. Clin Genitourin Cancer (2015) 0.79
Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis. PLoS One (2015) 0.78
Breast cancer therapy for BRCA1 carriers: moving towards platinum standard? Hered Cancer Clin Pract (2009) 0.78
Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs. J Biol Chem (2017) 0.75
Stemming the tide of cancer for BRCA1/2 mutation carriers. J Clin Oncol (2008) 0.75
[Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer]. Strahlenther Onkol (2012) 0.75
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Gene-expression profiles in hereditary breast cancer. N Engl J Med (2001) 29.80
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature (2005) 19.13
Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med (2000) 12.34
Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A (2005) 10.85
DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet (2001) 10.77
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70
Biallelic inactivation of BRCA2 in Fanconi anemia. Science (2002) 9.31
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst (2003) 8.48
Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science (1999) 6.93
Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res (2001) 6.78
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38
BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer (2004) 6.24
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol (2002) 6.16
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol (2002) 5.20
The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem (2000) 4.49
Involvement of Brca2 in DNA repair. Mol Cell (1998) 4.41
In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature (2000) 4.38
BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo. Cancer Res (1999) 4.16
Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med (2003) 4.04
CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet (2004) 3.97
Improved survival in women with BRCA-associated ovarian carcinoma. Cancer (2003) 3.96
Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol (2004) 3.88
Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA (2000) 3.69
Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest (2002) 3.36
Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet (2001) 2.82
Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation. Cancer Res (2001) 2.76
AlphaB-crystallin is a novel oncoprotein that predicts poor clinical outcome in breast cancer. J Clin Invest (2006) 2.74
Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer. Cancer Res (2005) 2.73
BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res (2003) 2.51
Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol (2006) 2.40
The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res (2004) 2.38
Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res (2006) 2.34
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer (2003) 2.26
Double-strand break repair deficiency and radiation sensitivity in BRCA2 mutant cancer cells. J Natl Cancer Inst (1998) 2.21
Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene (1999) 2.09
A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. Proc Natl Acad Sci U S A (2001) 2.09
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res (2003) 2.09
Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest (2002) 2.06
Biological and prognostic significance of stratified epithelial cytokeratins in infiltrating ductal breast carcinomas. Virchows Arch (1998) 2.00
BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res (1998) 1.97
TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. Clin Cancer Res (2003) 1.89
Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst (2002) 1.87
Tracing the network connecting BRCA and Fanconi anaemia proteins. Nat Rev Cancer (2004) 1.76
Fanconi anaemia. J Med Genet (2003) 1.70
TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: distinctive spectrum and structural distribution. Cancer Res (2001) 1.69
Core biopsies can be used to distinguish differences in expression profiling by cDNA microarrays. J Mol Diagn (2002) 1.67
ERBB2, TBX2, RPS6KB1, and MYC alterations in breast tissues of BRCA1 and BRCA2 mutation carriers. Genes Chromosomes Cancer (2004) 1.64
The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res (2000) 1.62
Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol (2002) 1.60
A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. Cancer Epidemiol Biomarkers Prev (2001) 1.51
Survival in familial, BRCA1-associated, and BRCA2-associated epithelial ovarian cancer. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) Familial Ovarian Cancer Study Group. Cancer Res (1999) 1.51
A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. Br J Cancer (2004) 1.41
Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. Semin Surg Oncol (2000) 1.40
Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology (2003) 1.38
Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer (2003) 1.38
A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet (2002) 1.35
Monoclonal marker that predicts early recurrence of breast cancer. Lancet (1987) 1.26
MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res (2004) 1.18
Germline BRCA1/2 mutations and p27(Kip1) protein levels independently predict outcome after breast cancer. J Clin Oncol (2000) 1.16
Hereditary breast cancer. Curr Probl Surg (2001) 1.14
The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res (2005) 1.12
The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells. Int J Oncol (2003) 1.12
Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A. Cancer Chemother Pharmacol (2004) 1.07
BRCA1 facilitates stress-induced apoptosis in breast and ovarian cancer cell lines. J Biol Chem (2000) 1.06
Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations. Eur J Surg Oncol (2001) 1.02
Revisiting the rodent repairadox. Environ Mol Mutagen (2001) 1.01
Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene (2003) 0.99
Tumor classification using phylogenetic methods on expression data. J Theor Biol (2004) 0.99
Low expression of bcl-2 in Brca1-associated breast cancers. Br J Cancer (2000) 0.91
Survival analysis in familial ovarian cancer, a case control study. Eur J Obstet Gynecol Reprod Biol (2001) 0.89
Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer. Br J Cancer (2003) 0.88
The contribution of inherited factors to the clinicopathological features and behavior of breast cancer. J Mammary Gland Biol Neoplasia (2001) 0.88
Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease. Oncologist (2002) 0.86
Are BRCA1- and BRCA2-related breast cancers associated with increased mortality? Breast Cancer Res (2004) 0.84
Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers. Breast Cancer Res Treat (2003) 0.82
Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers. Mol Pathol (2001) 0.82
Genetic counselling for familial breast and ovarian cancer in Ontario. J Med Genet (2002) 0.77
Sensitivity of BRCA-1-related breast cancer to neoadjuvant chemotherapy: practical implications. Breast J (2003) 0.77
Frequent disease progression and early recurrence in patients with familial ovarian cancer primarily treated with paclitaxel and cis- or carboplatin (preliminary report). Eur J Gynaecol Oncol (2003) 0.75